Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Volume 21(2); 2023 > Article
Corrigendum Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh1, Hee Seung Hong1, Nam Seok Ham1, Jungbok Lee2, Sang Hyoung Park1,3,4, Suk-Kyun Yang1,3,4, Hyuk Yoon5, You Sun Kim6, Chang Hwan Choi7, Byong Duk Ye1,3,4, on behalf of the Korean Association for the Study of Intestinal Diseases
Intestinal Research 2023;21(2):273-273.
DOI: https://doi.org/10.5217/ir.2021.00173.e
Published online: April 28, 2023

1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

4Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea

5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

6Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea

7Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

© Copyright 2023. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev
  • 2,098 Views
  • 147 Download
Full Article

Download PDF Download PDF

This corrects the article "Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study" on page 137.
https://doi.org/10.5217/ir.2021.00173
Intest Res 2023;21(1):137-147
In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.
“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2).”
  • 1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res 2023;21:137–147.ArticlePubMedPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
        Intest Res. 2023;21(2):273-273.   Published online April 28, 2023
        DOI: https://doi.org/10.5217/ir.2021.00173.e
        Close
      • XML DownloadXML Download
      Related articles
      Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
      Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
      Intest Res : Intestinal Research
      © Korean Association for the Study of Intestinal Diseases.
      Close layer
      TOP